2022 China Medical Beauty Industry Research Report - Simplified Version Source: iResearch Consulting
Market dynamics, consumer insights, advanced biomaterials, and regulatory trends
China Medical Aesthetics Industry Report 2022
iResearch Consulting · Market dynamics, consumer insights, advanced biomaterials, and regulatory trends
📑 Report Index
- 1. Definition & Classification
- 2. Market Size & Growth
- 3. Consumer Profiling
- 4. Industry Chain Overview
- 5. Hyaluronic Acid & Botulinum Toxin
- 6. Regenerative & Active Materials
- 7. Collagen & Bone-filling Materials
- 8. Energy-based Devices (Light & RF)
- 9. Aesthetic Clinics & Channel Evolution
- 10. Benchmark Cases: Imeik, Jinbo, Alma, Qizhi
- 11. Future Trends & Regulation
1. Medical vs. Cosmetic (Lifestyle) Beauty
Medical aesthetics refers to the use of surgical, drug, medical device, or other invasive techniques to reshape human appearance and morphology.
It is strictly regulated by the “Medical Beauty Service Management Measures”.
Lifestyle beauty is non-invasive, non-medical, and managed by the human resources department.
Key differences: environment (sterile OR required for medical), practitioner qualifications (licensed physicians), and regulatory oversight.
Legal framework Surgical vs. non-surgical: light medical aesthetics (injectables, energy-based) has lower risk and faster recovery, fueling growth.
2. Market Size: Light Aesthetics Becomes Dominant
Post-pandemic recovery began in 2021.
Non-surgical (light medical aesthetics) outpaces surgery due to anti-aging demand, low trauma, and minimal downtime.
By 2025, non-surgical procedures will likely become the main market driver.
3. Consumer Insight & Persona
Gender & age: 87% female; 68.4% aged 26-40 (post-80s & post-90s dominate).
Income: 63.4% monthly income between RMB 8k-20k; household income RMB 20k-50k for 46.5%.
City tier: 49.5% tier-2 cities, 31.3% tier-1 cities.
First aesthetic experience age is trending younger. Primary motivation: self-satisfaction (improve appearance for personal happiness, not just social pressure).
Around 40% wish to correct defects; less than 20% follow trends blindly. Post-90s show high independence.
4. Medical Aesthetics Industrial Chain
Upstream: raw materials (HA, botulinum toxin, PLLA, medical devices).
Midstream: aesthetic hospitals/clinics (≈17,000 licensed in 2021, private sector accounts for 90%).
Downstream: marketing channels (offline ads → search engines → vertical e-commerce platforms → private-domain traffic).
5. Fillers Mainstream: HA & Botulinum Toxin
💧 Hyaluronic acid (HA)
Widely used for facial contouring, wrinkle filling, and new applications like "elf ear" and "right-angle shoulder".
Nearly 40% of users received HA injection in the past year (2022).
Future body contouring (e.g., hip augmentation) may become a new frontier.
🧪 Botulinum Toxin
Market share among injectables rose from 32.7% (2019) to 52.9% (2021).
Features high safety, multi-area synergy (ant wrinkle + shaping), and high repurchase rate.
Combined with other therapies to achieve "1+1>2" results, strong customer retention.
6. Next-gen: Regenerative Materials & Active Ingredients
Regenerative (PLLA/PCL): stimulate collagen regeneration to restore volume, natural long-lasting effects. Products: Aijilan (PLLA), Radiesse-like structural fillers, Yiyan (PCL).
Active materials: non-crosslinked HA + nutrient complex (e.g., Imeik's Hyaluronic Acid series "Hi Body").
Active materials rejuvenate collagen via bioactive mechanism; shallow dermis injection, minimal side effects.
Market forecast: active materials to reach RMB 113.7B by 2030.
| Property | Active Materials (Hi Body) | Regenerative (PLLA/PCL) | HA (traditional) |
|---|---|---|---|
| Injection layer | Superficial dermis | Deep subcutaneous | Mid to deep dermis |
| Mechanism | Modulate & activate autologous collagen | Intense collagen neogenesis | Volumetric filler (foreign material) |
| Duration / retouch | Short interval (approx 3 months) | Long-lasting (6-9 months) | Varies by crosslinking |
| Adverse events | Rare nodules/swelling | Occasional inflammatory reactions | Tyndall effect, nodules |
Active materials represent a new paradigm for customized anti-aging and drive clinic profitability.
7. Collagen & Bone-filling Microspheres
Collagen fillers: superior for dynamic thin skin areas and tone brightening.
However, mass production constraints (animal-derived immunogenicity / recombinant technology challenges).
Jinbo Bio's recombinant type III humanized collagen (approved NMPA class III) overcomes prior limitations, with 183% higher cell adhesion.
Bone-stimulating materials (PMMA/PVA microspheres): injected at periosteum, stimulate long-term collagen for structural anti-aging. Represented by Aibifei (PMMA) and Baonida (PVA).
Strict safety control required due to permanence.
8. Energy-based Tech: Laser, IPL, RF, Ultrasound + Cryolipolysis
Main technologies: laser, intense pulsed light, radiofrequency (RF), ultrasound.
Laser hair removal ranks #1 in global energy-based procedures (Alma’s Ice Hair Removal leads in China).
RF for skin tightening; ultrasound provides deep lift but lacks domestic NMPA class III certification.
Recently approved cryolipolysis (coolsculpting) for abdomen/waist becomes emerging hot segment.
2020 laser device market: Alma leads, while Qizhi Laser and半岛医療 expand via proprietary tech.
9. Aesthetic Clinics & Customer Acquisition Evolution
In 2021, about 17,000 licensed aesthetic institutions, 90% private, highly fragmented with irregular practices.
Stricter regulation and consumer awareness push industry consolidation.
Marketing shift: Offline ads (before 2007) → Search engine bidding (2007-2020) → E-commerce & vertical platforms (Xin Yang, Meituan) → Private-domain traffic (2020+).
Private domain (WeChat, TikTok, KOL livestream) reduces costs, boosts retention and word-of-mouth referral.
10. Leading Players and Innovations
🌟 Imeik Technology – Active material "Hi Body" franchise
Hi Body is China's first neck line correction filler with class III medical device registration.
Revenue grew from RMB 30M (2017) to RMB 1.05B (2021), >100% annual growth.
Product matrix expands to periorbital (Hi Body Panda) and anti-glycation (Bonita Bubble).
🔬 Jinbo Bio – Recombinant type III humanized collagen
First company to mass-produce recombinant human collagen with 100% matching amino acid sequence.
Excellent safety profile (no immune rejection, high hydrophilicity).
⚡ Alma Lasers (Fosun / Sisram) – Energy devices leader
Flagship "three gold" series: HyperTherm, DPL, and Platinum Milk Light (skin tightening and whitening).
🇨🇳 Qizhi Laser – Homegrown R&D, laser / phototherapy equipment
Over 100 patents, hybrid direct sales + distribution model, driving import substitution.
11. Future Outlook & Regulatory Intensity
Regulation continues to deepen: from basic licensing to specific materials (regenerative/active) to ensure transparency and safety.
Clinics are shifting to data-driven operation models using active materials as a core attraction.
Active materials expected to exceed RMB 113.7 billion by 2030, becoming high-margin segment.
Combination protocols (energy + injectables + active substances) will dominate premium anti-aging offerings.
📌 Supplementary Insight: Injectables Composition & Self-motivation
According to SoYoung data & iResearch 2022 survey, Botox accounted for 52.9% of injectable consumption (2021).
Nearly 40% of first-time users choose medical aesthetics to "improve flaws for personal happiness", challenging the stereotype of external pressure.
Laser hair removal and intense pulsed light remain top energy-based procedures. Social media interest in "Radiesse-like" and "PLLA" fillers rises significantly.
*Based on iResearch "2022 China Medical Aesthetics Industry Report". Visual charts represent conceptual data; full report includes detailed regulatory timeline & competitive mapping.
